Innoviva (INVA) Profit After Tax Growth (1y) (2011 - 2026)
Powered by 
Analysis
Innoviva (INVA) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -8.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 94.83% |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | -230.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -230.98% |
| Mar 31, 2026 | -414.43% |
| Dec 31, 2025 | -4,880.69% |
| Sep 30, 2025 | 3,397.12% |
| Jun 30, 2025 | 277.49% |
| Mar 31, 2025 | -3.82% |
| Dec 31, 2024 | 113.10% |
| Sep 30, 2024 | -97.41% |
| Jun 30, 2024 | -26.56% |
| Mar 31, 2024 | -228.69% |
| Dec 31, 2023 | -92.43% |
| Sep 30, 2023 | -59.04% |
| Jun 30, 2023 | -17.95% |
| Mar 31, 2023 | -7.91% |
| Dec 31, 2022 | -70.56% |
| Sep 30, 2022 | -10.71% |
| Jun 30, 2022 | -121.68% |
| Mar 31, 2022 | -65.49% |
| Dec 31, 2021 | 8.71% |
| Sep 30, 2021 | 676.50% |